Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
2.740
+0.120 (4.58%)
At close: Jul 30, 2025, 4:00 PM
2.690
-0.050 (-1.82%)
After-hours: Jul 30, 2025, 6:55 PM EDT
Taysha Gene Therapies Market Cap
Taysha Gene Therapies has a market cap or net worth of $588.17 million as of July 30, 2025. Its market cap has increased by 19.70% in one year.
Market Cap
588.17M
Enterprise Value
533.21M
1-Year Change
19.70%
Ranking
Category
Stock Price
$2.74
Market Cap Chart
Since the IPO on September 24, 2020, Taysha Gene Therapies's market cap has decreased from $690.43M to $588.17M, a decrease of -14.81%. That is a compound annual growth rate of -3.25%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jul 30, 2025 | 588.17M | 65.89% |
| Dec 31, 2024 | 354.55M | 7.14% |
| Dec 29, 2023 | 330.92M | 134.50% |
| Dec 30, 2022 | 141.12M | -68.52% |
| Dec 31, 2021 | 448.22M | -55.28% |
| Dec 31, 2020 | 1.00B | 45.15% |
| Sep 24, 2020 | 690.43M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 689.95B |
| Johnson & Johnson | 403.85B |
| AbbVie | 338.53B |
| UnitedHealth Group | 240.44B |
| Novo Nordisk | 238.11B |
| Novartis AG | 227.32B |
| AstraZeneca | 224.29B |
| Abbott Laboratories | 221.83B |